Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


24 Osteoporose in der Onkologie: Literatur

Autor/en: R. Bartl
Letzte Änderung: 25.01.2006
  • Bartl R.
    Osteoporose - Prävention, Diagnostik, Therapie.
    Stuttgart, New York: Thieme 2001.


  • Bartl R, Bartl C.
    Osteoporose-Manual: Diagnostik, Prävention, Therapie.
    Heidelberg: Springer 2004.


  • Bartl R, Frisch B.
    Biopsy of bone in internal medicine - an atlas and sourcebook.
    Dordrecht, Boston, London: Kluwer Academic Publishers 1993.


  • Bartl R, Frisch B.
    Das Bisphosphonat-Manual: Wirkungen, Indikationen, Strategien, Trends.
    Berlin: Blackwell 2001.


  • Cohen A, Shane E.
    Osteoporosis after solid organ and bone marrow transplantation.
    Osteoporos Int 2003;14:617-630. PM:12908095
    [Medline]


  • Cummings S, Cosman F, Jamal S.
    Osteoporosis: An evidence-based guide to prevention and therapy.
    Philadelphia: American College of Physicians 2002.


  • Diel I, Possinger K (Hrsg).
    Bisphosphonate in der Onkologie.
    Bremen: Uni-Med 1999.


  • Emkey R, Delmas P, Goemaere S et al.
    Changes in bone mineral density following discontinuation of alendronate therapy of glucocorticoid-treated patients: a retrospective, observational study.
    Arthritis Rheum 2003;48:1102-1108. PM:12687554
    [Medline]


  • Finkelstein J, Hayes A, Hunzelman J et al.
    The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
    N Engl J Med 2003;349:1216-1226. PM:14500805
    [Medline]


  • Rehman Q, Lane N.
    Effect of glucocorticoids on bone density.
    Med Pediatr Oncol 2003;41:212-216. PM:12868121
    [Medline]


  • Ringe J, Dorst A, Faber H et al.
    Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
    Rheumatology 2003;42:743-749. PM:12730532
    [Medline]


  • Saag K, Emkey R, Schnitzer T et al.
    Alendronate for the treatment of glucocorticoid-induced osteoporosis.
    N Engl J Med 1998;339:292-299. PM:9682041
    [Medline]


  • Santini D, Vespasiani G, Vincenti B.
    The antineoplastic role of bisphosphonates: from basic research to clinical evidence.
    Ann Oncol 2003;14:1468-1476. PM:14504045
    [Medline]


  • Smith I, Dowsett M.
    Aromatase inhibitors in breast cancer.
    N Engl J Med 2003;348:2431-2442. PM:12802030
    [Medline]


  • Van Staa T, Leufkens H, Cooper C.
    The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.
    Osteoporos Int 2002;13:777-787. PM:12378366
    [Medline]


  • Wallach S, Cohen S, Reid D et al.
    Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
    Calcif Tissue Int 2000;67:277-285. PM:11000340
    [Medline]


Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"
Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag
[Mehr]